gt1b

Ledipasvir D-tartrate with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon. is an inhibitor of the hepatitis C virus NS5A.

Grazoprevir (MK-5172) 是一种氮杂大环化合物，被作为丙型肝炎病毒 NS3 4A 蛋白酶抑制剂。Grazoprevir 常与 elbasvir 联合用于治疗成人慢性 HCV 基因型 1 或 4 感染。

Ganglioside GT1b is a trisialoganglioside that is characterized by having two sialic residues linked to the inner galactose unit. It binds to the neurotoxins botulinum toxin serotype A (BTxA), BTxA heavy chain, and tetanus toxin with IC50 values of 11, 0.74, and 7.2 μM, respectively.[1] Ganglioside GT1b-containing liposomes bind to the major coat protein VP1 from Merkel cell polyomavirus (MCPyV), which has been identified in Merkel cell carcinomas, identifying ganglioside GT1b as a putative MCPyV receptor. [2] Ganglioside GT1b decreases production of IL-6, IL-10, IgG, IgM, and IgA in human peripheral blood mononuclear cells (PBMCs) by 31.4, 30.5, 60, 59.5, and 58%, respectively, when used at a concentration of 10 μM [3] . Ganglioside GT1b mixture contains ganglioside GT1b molecular species with C18:1 and C20:1 sphingoid backbones.

Ledipasvir (GS-5885) 是一种丙型肝炎病毒 NS5A 抑制剂。它也是 P-糖蛋白抑制剂和乳腺癌抗性蛋白抑制剂。

PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977)(IC50s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively).

Grazoprevir is a drug approved for the treatment of hepatitis C. Grazoprevir is a second-generation hepatitis C virus protease inhibitor acting at the NS3 4a protease targets.

Grazoprevir, a second generation hepatitis C virus protease inhibitor acting at the NS3/4a protease targets, has good activity against a range of hepatitis C virus genotype variants, including some that are resistant to most currently used antiviral medic

ABT-072, also known as potassium trihydrate, is a highly effective non-nucleoside inhibitor of the HCV NS5B polymerase, administered orally. This compound exhibits potent activity against HCV GT1a (with an EC50 of 1 nM) and HCV GT1b (with an EC50 of 0.3 nM).

Ledipasvir (acetone) (GS-5885 acetone) 是 Ledipasvir 的活性药物成分。Ledipasvir 是一种 HCV NS5A 聚合酶抑制剂，用于治疗丙型肝炎病毒感染。

GSK5852 (GSK2485852) 是 HCV NS5B RdRp 聚合酶抑制剂。GSK5852 能够抑制NS5B (IC50: 50 nM)。GSK5852 表现出抗病毒效果，能够丙型肝炎病毒 (HCV)，对 GT1a 和 GT1b 的 EC50 值分别为 3.0 nM 和 1.7 nM。

HCV-IN-39 (Compound 18a) 是一种有效的、口服具有活力的 hepatitis C virus (HCV) 核苷抑制剂，能够作用于 GT1a 复制子 (EC50: 0.259 μM)、GT1b 复制子 (EC50: 0.434 μM) 和 GT1b CES1 复制子 (EC50: 0.069 μM)。

NS5A-IN-4 (Compound 1.12) 是一种具有口服活性的泛基因型丙型肝炎病毒 (HCV)NS5A 抑制剂，对gT1b、gT1a、gT2a、gT3a,gT4a 和gT5a 的IC50分别为 1.2、2296、4.6、362、10.3 和 693 pM。

Ledipasvir (GS-5885) hydrochloride 是抗HCV NS5A 的高效抑制剂，对GT1a 和 GT1b 复制子抑制作用显著，其EC50值仅为34 pM 和 4 pM。此外，Ledipasvir hydrochloride 还能抑制 SARS-CoV 3CLpro， IC50 为1.62 μM。